The development of novel inhibitors of tumor necrosis factor-α (TNF-α) production based on substituted [5,5]-bicyclic pyrazolones

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 16, 2004, Pages 4267-4272

  Laufersweiler, Matthew J ^a   Brugel, Todd A ^a   Clark, Michael P ^a   Golebiowski, Adam ^a   Bookland, Roger G ^a   Laughlin, Steven K ^a   Sabat, Mark P ^a   Townes, Jennifer A ^a   VanRens, John C ^a   De, Biswanath ^a   Hsieh, Lily C ^a   Heitmeyer, Sandra A ^a   Juergens, Karen ^a   Brown, Kimberly K ^a   Mekel, Marlene J ^a   Walter, Richard L ^a   Janusz, Michael J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Cytokine synthesis inhibition; Kinases; p38; Pyrazolones; TNF

Indexed keywords

BLOCKING AGENT; IODOACETIC ACID; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRAZOLONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG SYNTHESIS; GENE MUTATION; HUMAN; HUMAN CELL; MONOCYTIC LEUKEMIA; MYELOID LEUKEMIA; NONHUMAN; OSTEOARTHRITIS; RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; LIPOPOLYSACCHARIDES; MODELS, MOLECULAR; PYRAZOLONES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3142677902     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.06.001     Document Type: Article

References (24)

1. For recent reviews, see: Palladino M.A., Bahjat F.R., Theodorakis E.A., Moldawer L.L. Nat. Rev. Drug Discovery. 2:2003;736-746
2. Baugh J.A., Bucala R. Curr. Opin. Drug Discovery Dev. 4:2001;635-650
3. Adams J.L., Badger A.M., Kumar S., Lee J.C. King F.D., Oxford A.W. Progress in Medicinal Chemistry. Vol. 38:2001;1-60 Elsevier, Amsterdam
4. Chen Z., Gibson T.B., Robinson F., Silvestro L., Pearson G., Xu B.-e., Wright A., Vanderbilt C., Cobb M.H. Chem. Rev. 101:2001;2449-2476
5. Smolen J.S., Seiner G. Nat. Rev. Drug Discovery. 2:2003;473
6. Pearce G.J., Chikanza I.C. BioDrugs. 15:2001;139-149
7. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleisenmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koupman W.J., Mohler K., Widmer M.B., Blosch C.M. N. Engl. J. Med. 337:1997;141-153
8. Brennan F.M., Feldman M. Curr. Opin. Immunol. 8:1996;872-877
9. Camussi G., Lupia E. Drugs. 55:1998;613-620
10. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., Mayer L., Van Hogezand R.A., Braakman T., DeWoody K.L., Schaible T.F., Van Deventer S.J.H. Gastroenterology. 117:1999;761-769
11. Gallagher T.F., Fier-Thompson S.M., Garigipati R.S., Sorenson M.E., Smietana J.M., Lee D., Bender P.E., Lee J.C., Laydon J.T., Chabot-Fletcher M.C., Breton J.J., Adams J.L. Biorg. Med. Chem. Lett. 5:1995;1171-1174
12. Wilson K.P., McCaffrey P.G., Hsiao K., Pazhanisamy S., Galullo V., Bemis G.W., Fitzgibbon M.J., Caron P.R., Murcko M.A., Su M.S.S. Chem. Biol. 4:1997;423-431
13. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., Goldsmith E.J. Structure. 6:1998;1117-1128
14. Smolen J.S., Steiner G. Nat. Rev. Drug Discovery. 2:2003;473-488
15. Clark M.P., Laughlin S.K., Laufersweiler M.J., Bookland R.G., Brugel T.A., Golebiowski A., Sabat M.P., Townes J.A., VanRens J.C., Djung J.F., Natchus M.G., De B., Hsieh L.C., Xu S.C., Walter R.L., Mekel M.J., Heitmeyer S.A., Brown K.K., Juergens K., Taiwo Y.T., Janusz M.J. J. Med. Chem. 47:2004;2724-2727
16. 10 (Promega Co., Madison, WI)
17. Mohler K.M., Sleath P.R., Fitzner J.N., Cerretti D.P., Alderson M., Kerwar S.S., Torrance D.S., Otten-Evans C., Greenstreet T., Weerawarna K., Kronhelm S.R., Petersen M., Gerhart M., Kozlosky C.J., March C.J., Black R.A. Nature. 370:1994;218-220
18. Barltrop J.A., Owen T.C., Cory A.H., Cory J.G. Bioorg. Med. Chem. Lett. 1:1991;611-614
19. 1 ; a=65.2 Å, b=74.6 Å, c=78.1 Å (4′). X-ray data were collected at beamline 17-BM in the facilities of the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) at the Advanced Photon Source. These facilities are supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Illinois Institute of Technology (IIT), executed through IIT's Center for Synchrotron Radiation Research and Instrumentation. Use of the Advanced Photon Source was supported by the U. S. Department of Energy, Basic Energy Sciences, Office of Science, under Contract No. W-31-109-Eng-38
20. Han J., Lee J.D., Bibbs L., Ulevitch R.J. Science. 265:1994;808-811
21. Wang Z., Harkins P.C., Ulevitch R.J., Han J., Cobb M.H., Goldsmith E.J. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2327-2332
22. Pav S., Whit D.M., Rogers S., Crane K.M., Cywin C.L., Davidson W., Hopkins J., Brown M.L., Pargellis C.A., Tong L. Protein Sci. 6:1997;242-245
23. 16
24. Guingamp C., Gegout-Pottie P., Philippe L., Terlain B., Netter P., Gillet P. Arthritis Rheum. 40:1997;1670